tert-butyl 6'-fluoro-1'-methyl-2'-oxo-1',2'-dihydrospiro[azetidine-3,4'-benzo[d][1,3]oxazine]-1-carboxylate | 1563182-61-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tert-butyl 6'-fluoro-1'-methyl-2'-oxo-1',2'-dihydrospiro[azetidine-3,4'-benzo[d][1,3]oxazine]-1-carboxylate
• CAS: 1563182-61-5
• 化学式: C₁₆H₁₉FN₂O₄
• 分子量: 322.336
• InChiKey: JCONEMYBJJBHMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.86
• 重原子数：
  23.0
• 可旋转键数：
  0.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  59.08
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 6'-fluoro-1'-methyl-2'-oxo-1',2'-dihydrospiro[azetidine-3,4'-benzo[d][1,3]oxazine]-1-carboxylate 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 12.0h， 以57%的产率得到6'-fluoro-1'-methylspiro[azetidine-3,4'-benzo[d][1,3]oxazin]-2'(1'H)-one
  参考文献：
  名称：

  Design, Synthesis, and Optimization of Balanced Dual NK₁/NK₃Receptor Antagonists

  摘要：

  In connection with a program directed at potent and balanced dual NK1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pK(i) values of 8.6 and 8.1, respectively.

  DOI：

  10.1021/ml400528y
• 作为产物：
  描述：

  N-Boc-3-羟基氮杂环丁烷 在 四丙基高钌酸铵 、 叔丁基锂 、 caesium carbonate 、 N-甲基吗啉氧化物 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 乙腈 、 正戊烷 为溶剂， 反应 53.92h， 生成 tert-butyl 6'-fluoro-1'-methyl-2'-oxo-1',2'-dihydrospiro[azetidine-3,4'-benzo[d][1,3]oxazine]-1-carboxylate
  参考文献：
  名称：

  Design, Synthesis, and Optimization of Balanced Dual NK₁/NK₃Receptor Antagonists

  摘要：

  In connection with a program directed at potent and balanced dual NK1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pK(i) values of 8.6 and 8.1, respectively.

  DOI：

  10.1021/ml400528y